Semaglutide, a GLP-1 receptor agonist, effectively lowers blood glucose levels, supports weight management reduces major cardiovascular events, decreases postprandial inflammation (PMID: 32910488, PMID: 32910487, PMID: 33068776 ).

CJC-1295/Ipamorelin is a dual-peptide research blend combining two mechanistically distinct growth hormone (GH) secretagogues that act synergistically on the hypothalamic–pituitary axis. CJC-1295 is a 29-amino acid analog of growth hormone-releasing hormone (GHRH) and a tetra-substituted derivative of the shortest functional GHRH sequence, with substitutions that support stability against proteolytic degradation and improve receptor interaction. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that displays high GH-releasing potency and efficacy both in vitro and in vivo. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that displays high GH-releasing potency and efficacy both in vitro and in vivo (PMID: 9849822)